Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocarcinoma~* T2-4 NX M0 disease~* ECOG performance status 0-1~* adequate hematological status~* adequate renal function~* adequate hepatic function~* adequate metabolic function~Exclusion Criteria:~* pregnant or breast feeding women~* previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix~* arterial or venous thromboembolism within 6 months before enrollment~* clinically significant cardiovascular disease within 1 year before enrollment~* history of interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): 3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1

Based on this trial design, predict the completion outcome and termination type (if applicable).